Developed by the São Paulo-based Butantan Biological Institute, the ButanVac coronavirus vaccine showed “an acceptable safety profile and potent immunogenicity” in clinical trials held in Thailand.
A pre-print version of the study was published by researchers from Bangkok’s Mahidol University, the Icahn School of Medicine at Mount Sinai, and the University of Texas at Austin.
The study shows that “there were no vaccine-related serious adverse events.” The vaccine is also being tested in Brazil and Vietnam, but trial data from the two countries have not been made available so far.
Developed from technology patented by the Icahn School of Medicine, ButanVac was advertised as a way to give Brazilian labs the scale and autonomy needed to speed up the immunization process. But it should only be ready for distribution in later stages of vaccination — almost 70 percent of Brazilians have gotten at least one shot and 40 percent are fully immunized.